Biliary Tract Disorders including cancer Break out session, KI-Mayo Meeting 2023

Program Chairs and Moderators: Dr. Gregory Gores (MC), Dr. Niklas Björkström (KI)
Please note that minor change in the agenda might occur.

Biliary Tract Disorders including cancer

9:00- 10:50 AM (Rochester) /16:00- 17:50 PM (Stockholm);

Welcome and Overview of Session Day One

9.00am/16.00pm: Introduction to session
Dr. Gregory Gores (MC), Dr. Niklas Björkström (KI)

9.10am/16.10pm: Increased Prevalence of Alpha-1-Antitrypsin Deficiency in Patients with Biliary Tract Cancer and Its Associated Clinicopathological Features
Dr. Martin Cornillet (KI) - Virtual

9.35am/16.35pm: The epigenetic reader, BRD2, mediates cholangiocyte senescence via interaction with ETS1Dr. Steven O'Hara (MC)

10.00am/17.00pm:Characterizing innate lymphoid cells in the human biliary tract system
Daniel Geanon (KI)
10.25am/17.25pm: IL-17 Signaling in Primary Sclerosing Cholangitis Patient-Derived Organoids
Dr. Ana Sofia Garcia Moreno (MC)
10.50am/17.50pm: Concluding discussions
All speakers + chairs
12:00am/19:00pm: Murdock Lecture

8:00 - 11:05 AM (Rochester) /15:00- 18:05 PM (Stockholm)

Welcome and Overview of Session Day Two

8.00am/15.00pm: Introduction to session
Dr. Gregory Gores (MC), Dr. Niklas Björkström (KI)
8.05am/15.05pm:Deciphering heterogeneity of natural killer cells within the cholangiocarcinoma microenvironment
Dr. Iva Filipovic (KI) (PhD) - Virtual
8.30am/15.30pm:The Swedish initiative for the study of Primary sclerosing cholangitis (SUPRIM)
Dr. Martin Cornillet (KI) - Virtual
8.55am/15.55pm:Inflammation and Oxidative Stress in Primary Sclerosing Cholangitis
Dr. Nidhi Jalan-Sakrikar (MC)
9.20am/16.20pm: Genome-wide methylation profiling of biliary tract cancers reveals pathogenesis mecanisms and clinical applications
Dr. Ghada Nouairia (KI) - Virtual
Break
9.50am/16.50pm: Familial risk of biliary tract cancer and colorectal cancer in patients with primary sclerosing cholangitis
Dr. Erik von Seth (KI)
10:15am/17.15pm: Prospective surveillance of patients with primary sclerosing cholangitis for early detection of cholangiocarcinoma
Dr. Christina Villard (KI) - Virutal
10.40am/ 17.40pm: Long term effect of simvastatin in primary sclerosing cholangitits (PSC): a placebo-controlled, double-blind, multicenter phase III study (PiSCATIN)
Dr. Annika Bergquist (KI) - Virutal
11.05am/18.05pm:Concluding discussions
All speakers + chairs
18:15pm/11:15am: Lunch
19:00pm/12:00am: Plenary session

Coming soon